Factors associated with the use of adjuvant neratinib in stage I-III HER2-positive breast cancer.

被引：0
|
作者：
Stoen, Ericson
Kagihara, Jodi
Kabes, Pater
Fisher, Christine M.
Diamond, Jennifer Robison
机构：
[1] Univ Colorado, Sch Med, Aurora, CO USA
[2] Univ Colorado, Anschutz Med Campus, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12517
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Neratinib for the treatment of HER2-positive early stage breast cancer
    Echavarria, Isabel
    Lopez-Tarruella, Sara
    Marquez-Rodas, Ivan
    Jerez, Yolanda
    Martin, Miguel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (08) : 669 - 679
  • [2] Neratinib in Early-Stage HER2-Positive Breast Cancer
    Cherian, Mathew A.
    Ma, Cynthia X.
    BREAST DISEASES, 2015, 26 (04): : 285 - 287
  • [3] Neratinib in extended adjuvant therapy for HER2-positive early breast cancer
    Kubiatowski, Tomasz
    ONCOLOGY IN CLINICAL PRACTICE, 2020, 16 (04): : 201 - 205
  • [4] Neratinib extends adjuvant treatment of patients with HER2-positive breast cancer
    Abraham, Jame
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2018, 16 (04): : E185 - E187
  • [5] Use of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
    Elkerm, Y.
    Ali, I. M.
    Elsaid, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Neratinib in HER2-Positive Breast Cancer Patients
    Paranjpe, Rutugandha
    Basatneh, Dima
    Tao, Gabriel
    De Angelis, Carmine
    Noormohammed, Sobia
    Ekinci, Ekim
    Abughosh, Susan
    Ghose, Romi
    Trivedi, Meghana V.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (06) : 612 - 620
  • [7] Neratinib (Nerlynx) for HER2-Positive Breast Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2018, 60 (1539): : 23 - 23
  • [8] Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate
    Kotecki, N.
    Gombos, A.
    Awada, A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (06) : 447 - 454
  • [9] Neratinib in adjuvant treatment of patients with HER2-positive breast cancer - less is more?
    Cedrych, Ewa
    Cedrych, Ida
    ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (02): : 111 - 114
  • [10] Patterns in use and tolerance of adjuvant neratinib in patients with hormone receptor (HR)-positive, HER2-positive early-stage breast cancer
    Blanter, Julia
    Baldwin, Elena
    Patel, Rima
    Sheng, Tianxiang
    Tiersten, Amy
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 208 (02) : 461 - 466
12345